FIELD: medicine.
SUBSTANCE: invention relates to experimental medicine, and can be used for protection of post-vaccination immunity to tetanus anatoxin against methotrexate-induced depression. Method includes parenteral introduction of miliacin into experimental animal organism in dose 2 mg/kg of weight. Miliacin is introduced tree times daily to animals with formed post-vaccination immunity to tetanus anatoxin, subjected to immunodepressive impact of methotrexate cytostatic.
EFFECT: application of invention allows to protect formed post-vaccination immunity against immunodepressive impact of cytostatic due to anticatabolic action of miliacin.
5 dwg
Title | Year | Author | Number |
---|---|---|---|
AGENT ENHANCING IMMUNOGENIC PROPERTY OF TETANUS ANATOXIN | 2003 |
|
RU2244548C1 |
MEDICATION INCREASING ANTITUMOUR EFFECT OF METHOTREXATE | 2009 |
|
RU2411947C1 |
AGENT LIMITING LYMPHOTOXIN EFFECT OF METHOTREXATE | 2007 |
|
RU2337693C1 |
AGENT FOR REDUCING SYSTEMIC PATHOLOGIC ENDOTOXINEMIA | 2014 |
|
RU2564918C1 |
ANTIMUTAGENIC AGENT | 2019 |
|
RU2698204C1 |
METHOD FOR REDUCING GEMOTOXIC ACTION OF BENZENE ON AN ORGANISM | 2017 |
|
RU2724891C2 |
AGENT WITH IMMUNOPOTENTIATING ACTIVITY | 2007 |
|
RU2347562C2 |
METHOD FOR IMMUNIZATION IN PREGNANT COWS FOR PREVENTING VIRAL DIARRHEA AS MUCOSAL DISEASE IN CALVES | 2002 |
|
RU2212892C1 |
AGENT OF IMMUNOMODULATING ACTIVITY | 2007 |
|
RU2329821C1 |
AGENT OF IMMUNOMODULATING ACTIVITY | 2007 |
|
RU2337700C1 |
Authors
Dates
2010-07-20—Published
2008-12-25—Filed